{"filing":{"accession_number":"0001193125-26-323651","cik":"0001750149","ticker":"IKT","company_name":"Inhibikase Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"d78217d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526323651/d78217d8k.htm"},"events":[{"id":21588,"run_id":19475,"accession_number":"0001193125-26-323651","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Inhibikase issued a pre-funded warrant to acquire 18,030,000 shares of common stock without registration, relying on Section 3(a)(9) of the Securities Act. The warrant has a nominal $0.001 exercise price and is immediately exercisable, making it economically equivalent to a direct equity issuance. This is a classic dilutive unregistered equity transaction that would materially affect a reasonable investor's assessment of share dilution and capital structure.","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21262,"accession_number":"0001193125-26-323651","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibikase issued a pre-funded warrant to acquire 18,030,000 shares of common stock without registration, relying on Section 3(a)(9) of the Securities Act. The warrant has a nominal $0.001 exercise price and is immediately exercisable, making it economically equivalent to a direct equity issuance. This is a classic dilutive unregistered equity transaction that would materially affect a reasonable investor's assessment of share dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:08:11.807100+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21262,"accession_number":"0001193125-26-323651","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Inhibikase issued a pre-funded warrant to acquire 18,030,000 shares of common stock without registration, relying on Section 3(a)(9) of the Securities Act. The warrant has a nominal $0.001 exercise price and is immediately exercisable, making it economically equivalent to a direct equity issuance. This is a classic dilutive unregistered equity transaction that would materially affect a reasonable investor's assessment of share dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:08:11.807100+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-07-29"}]}